Mirum Pharmaceuticals, Inc.

MIRM

Mirum Pharmaceuticals, Inc.

MIRM

Insider Sentiment (TTM):

Last Purchase:2026-01-23Last Sale:2026-06-17Shares Purchased (TTM):131,425Shares Sold (TTM):374,091

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:65,211,191Shares Outstanding:58,851,021Institutional Ownership Pct.:110.81%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	331	325	297	282	228	212	223	223	233	303	286	303
Short Term Investments	108	61	87	94	76	66	58	61	45	-	0	3
Accounts Receivable Net Current	145	133	123	107	107	96	78	69	60	55	68	48
Inventory Net	26	26	25	24	23	22	22	22	20	22	22	22
Prepaid Expense And Other Assets Current	27	25	18	24	19	15	12	12	9	10	11	12
Assets Current	636	569	550	531	453	411	393	387	368	389	388	389
Restricted Cash And Cash Equivalents	2	2	1	0	0	0	0	0	0	-	0	-
Restricted Cash Equivalents	-	-	-	-	-	-	-	-	-	-	0	0
Long Term Investments	123	34	8	2	17	21	13	9	17	-	0	-
Property Plant And Equipment Net	2	2	2	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	12	13	9	9	9	8	9	9	9	1	1	1
Intangible Assets Net Excluding Goodwill	247	254	261	232	238	244	250	256	262	257	253	258
Other Assets Noncurrent	22	16	12	10	7	5	5	5	4	4	4	2
Assets	1,045	891	843	785	726	690	671	668	661	652	647	651
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	23	59	10	12	18	12	15	10	10	16	7	7
Accrued Liabilities Current	-	-	196	-	-	-	112	105	101	90	79	66
Derivative Liabilities Current	-	-	-	-	-	-	-	-	-	-	0	0
Operating Lease Liability Current	-	-	2	-	-	-	2	2	1	0	1	1
Asset Acquisition Contingent Consideration Liabili…	25	26	-	-	-	-	-	-	-	-	-	-
Liabilities Current	223	273	206	160	145	128	127	116	112	106	87	75
Operating Lease Liability Noncurrent	10	11	8	7	8	7	8	8	8	0	1	1
Convertible Long Term Notes Payable	750	310	310	309	309	309	308	308	307	307	306	306
Asset Acquisition Contingent Consideration Liabili…	61	48	-	-	-	-	-	-	-	-	-	-
Other Liabilities Noncurrent	11	6	5	16	9	14	3	4	4	4	4	0
Liabilities	1,055	648	528	493	471	457	445	436	432	417	398	382
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,515	1,700	982	954	920	892	870	851	836	816	803	791
Retained Earnings Accumulated Deficit	-1,525	-1,458	-668	-662	-665	-659	-644	-620	-606	-582	-556	-521
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	0	-0	-0	1	-0	-0	2	-1
Stockholders Equity	-10	242	315	292	255	233	226	232	229	235	249	269
Liabilities And Stockholders Equity	1,045	891	843	785	726	690	671	668	661	652	647	651
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	65	61	52	51	50	49	48	48	48	47	47	47
Shares Outstanding	65	61	52	51	50	49	48	48	48	47	47	47

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-7.79%	12.44%	2.68%	-	-	-	-	-	-	-	-	-
2025	7.86%	23.94%	25.74%	38.36%	36.28%	31.15%	2.93%	11.68%	32.86%	-18.51%	-9.82%	-5.92%
2024	-4.03%	36.54%	73.04%	10.65%	-0.28%	-0.18%	5.65%	1.23%	15.61%	-6.93%	-22.60%	-10.91%
2023	-	-	-	2.96%	23.05%	5.69%	13.95%	5.67%	-7.26%	-1.91%	-3.47%	-10.24%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.86	2.09	2.67	3.31	3.13	3.22	3.10	3.34	3.28	3.68	4.45	5.20
Quick Ratio	2.62	1.90	2.46	3.01	2.84	2.93	2.83	3.05	3.02	3.38	4.07	4.74
Working Capital	413.52M	296.61M	343.89M	370.22M	308.60M	283.24M	266.24M	270.88M	255.52M	283.56M	300.48M	313.92M
Leverage & Debt
Debt to Equity	-101.27	2.67	1.68	1.69	1.84	1.96	1.97	1.88	1.89	1.78	1.60	1.42
Interest Coverage TTM	-62.06	-55.27	-1.54	-2.91	-3.98	-5.33	-6.12	-5.18	-5.85	-5.81	-7.23	-15.17
Debt Ratio	1.01	0.73	0.63	0.63	0.65	0.66	0.66	0.65	0.65	0.64	0.62	0.59
Efficiency & Turnover
Asset Turnover TTM	0.70	0.72	0.69	0.65	0.62	0.57	0.51	0.47	0.48	0.45	0.37	0.29
Days Sales Outstanding TTM	74.47	73.36	70.58	67.95	71.13	72.59	79.23	69.17	66.10	64.90	90.05	80.92
Receivables Turnover TTM	4.90	4.98	5.17	5.37	5.13	5.03	4.61	5.28	5.52	5.62	4.05	4.51
Per Share Metrics
Diluted EPS TTM	-13.57	-13.57	-0.47	-0.73	-1.18	-1.58	-1.85	-2.09	-2.31	-3.38	-4.00	-3.99
Free Cash Flow Per Share TTM	-0.04	-2.93	1.09	0.91	0.21	-0.16	0.20	-0.15	-5.12	-5.43	-7.06	-7.34
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	81.39%	80.77%	79.92%	79.02%	77.10%	75.77%	72.68%	72.27%	73.26%	74.76%	-
Operating Profit Margin TTM	-134.93%	-139.82%	-4.25%	-8.86%	-13.30%	-20.12%	-26.00%	-31.26%	-41.01%	-48.43%	-58.57%	-76.51%
Net Profit Margin TTM	-139.18%	-140.24%	-4.48%	-8.78%	-13.65%	-20.39%	-26.10%	-32.51%	-41.29%	-70.79%	-87.68%	-113.45%
Growth Metrics
Net Revenue Growth (1Y)	44.02%	50.19%	54.74%	53.66%	62.33%	69.31%	80.76%	112.14%	128.34%	133.90%	141.85%	176.75%
Net Income Growth (1Y)	1,368.86%	932.90%	-73.43%	-58.50%	-46.35%	-51.22%	-46.18%	-39.21%	-38.08%	22.74%	20.45%	293.85%
EPS Growth (1Y)	1,052.55%	758.05%	-74.85%	-60.84%	-49.04%	-53.18%	-53.70%	-47.71%	-50.05%	-1.46%	-0.30%	234.71%
Valuation Metrics
P/E TTM	-8.62	-6.81	-169.72	-89.62	-43.21	-28.48	-22.34	-18.67	-14.79	-7.43	-7.39	-7.91
P/B TTM	-711.88	22.42	12.60	12.71	9.92	9.44	8.71	8.03	7.05	5.02	4.85	4.83
P/S TTM	12.00	9.54	7.61	7.87	5.90	5.81	5.83	6.07	6.11	5.26	6.48	8.97
Market Cap	7.42B	5.44B	3.97B	3.71B	2.53B	2.20B	1.97B	1.86B	1.61B	1.18B	1.21B	1.30B
Enterprise Value	7.84B	5.42B	3.98B	3.74B	2.61B	2.30B	2.05B	1.95B	1.69B	1.18B	1.23B	1.30B
Calculated Values
Free Cash Flow TTM	-2.60M	-172.55M	54.87M	46.32M	10.63M	-7.87M	9.33M	-7.20M	-241.98M	-254.80M	-288.82M	-301.71M
Net Debt	419.35M	-14.66M	13.11M	27.35M	80.81M	96.69M	85.58M	84.70M	74.00M	3.99M	20.10M	2.96M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-17Sale

Owner: Howe, Jolanda

Title: SVP, GLOBAL CONTROLLER

Shares: 2,594

Price/Share: $101.95

Value: $264,458.30

Shares Owned: 5,835

Relationship: Officer

Ownership: Direct

2026-06-08Sale

Owner: Bjerkholt, Eric

Title: CHIEF FINANCIAL OFFICER

Shares: 5,000

Price/Share: $93.97

Value: $469,850.00

Shares Owned: 44,788

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Peetz, Christopher

Title: CHIEF EXECUTIVE OFFICER

Shares: 30,000

Price/Share: $96.92

Value: $2,907,600.00

Shares Owned: 194,309

Relationship: Director,Officer

Ownership: Direct

2026-06-01Sale

Owner: Ramasastry, Saira

Title: -

Shares: 3,977

Price/Share: $100.00

Value: $397,700.00

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-05-15Sale

Owner: Ramasastry, Saira

Title: -

Shares: 2,000

Price/Share: $109.47

Value: $218,940.00

Shares Owned: -

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-17	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	2,594	101.95	$264,458.30	5,835	4
2026-06-08	Bjerkholt, Eric	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	5,000	93.97	$469,850.00	44,788	4
2026-06-01	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	30,000	96.92	$2,907,600.00	194,309	4
2026-06-01	Ramasastry, Saira	Director	-	Direct	Sale	3,977	100.00	$397,700.00	0	4
2026-05-15	Ramasastry, Saira	Director	-	Direct	Sale	2,000	109.47	$218,940.00	0	4
2026-04-15	Ramasastry, Saira	Director	-	Direct	Sale	2,000	96.90	$193,800.00	0	4
2026-03-16	Bjerkholt, Eric	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	7,287	91.98	$670,258.26	49,788	4
2026-03-16	Ramasastry, Saira	Director	-	Direct	Sale	2,000	90.76	$181,520.00	0	4
2026-03-16	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	40,985	91.98	$3,769,800.30	194,309	4
2026-03-16	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	16,515	91.98	$1,519,049.70	40,272	4
2026-03-16	Quan, Joanne	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	7,287	91.98	$670,258.26	18,864	4
2026-03-16	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	4,732	91.98	$435,249.36	8,429	4
2026-02-13	Ramasastry, Saira	Director	-	Direct	Sale	2,000	102.09	$204,180.00	0	4
2026-02-02	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	968	103.30	$99,994.40	4,503	4
2026-02-02	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	9,108	103.30	$940,856.40	160,294	4
2026-02-02	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	2,631	103.30	$271,782.30	20,655	4
2026-01-26	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	6,831	96.19	$657,073.89	169,402	4
2026-01-26	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	3,143	96.19	$302,325.17	23,286	4
2026-01-26	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	842	96.19	$80,991.98	3,700	4
2026-01-26	Bjerkholt, Eric	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,053	96.19	$101,288.07	43,741	4
2026-01-23	Heron, Patrick J	Director	-	Indirect	Purchase	131,425	68.48	$8,999,984.00	459,010	4
2026-01-22	Bjerkholt, Eric	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,421	93.33	$132,621.93	42,127	4
2026-01-22	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	926	93.33	$86,423.58	3,042	4
2026-01-22	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,098	93.33	$662,456.34	163,733	4
2026-01-22	Quan, Joanne	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,822	93.33	$170,047.26	12,817	4
2026-01-22	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	2,382	93.33	$222,312.06	20,679	4
2026-01-20	Quan, Joanne	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	6,911	90.27	$623,855.97	11,305	4
2026-01-15	Ramasastry, Saira	Director	-	Direct	Sale	2,000	90.99	$181,980.00	0	4
2025-12-22	Ramasastry, Saira	Director	-	Direct	Sale	5,000	80.00	$400,000.00	0	4
2025-12-19	Grey, Michael G	Director	-	Direct	Sale	50,000	78.00	$3,900,000.00	0	4
2025-12-18	Ramasastry, Saira	Director	-	Direct	Sale	2,000	69.73	$139,460.00	0	4
2025-12-01	Grey, Michael G	Director	-	Direct	Sale	50,000	74.00	$3,700,000.00	0	4
2025-11-21	Grey, Michael G	Director	-	Direct	Sale	50,000	70.00	$3,500,000.00	0	4
2025-09-12	Bjerkholt, Eric	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	9,578	76.01	$728,023.78	39,945	4
2025-09-11	Brege, Laura	Director	-	Direct	Sale	17,000	74.70	$1,269,900.00	15,703	4
2025-09-08	Ramasastry, Saira	Director	-	Direct	Sale	17,000	-	-	0	4
2025-08-11	Bjerkholt, Eric	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	8,000	-	-	28,236	4
2025-08-11	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	40,000	62.00	$2,480,000.00	138,641	4
2025-08-07	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	40,000	55.25	$2,210,000.00	138,641	4
2025-08-07	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	10,000	58.00	$580,000.00	2,426	4
2025-07-03	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	477	49.08	$23,411.16	2,426	4
2025-06-11	Fairey, William	Director	-	Direct	Sale	3,203	48.42	$155,089.26	2,500	4
2025-06-03	Ramasastry, Saira	Director	-	Direct	Sale	2,500	45.74	$114,350.00	0	4
2025-03-18	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	2,415	44.45	$107,346.75	2,426	4
2025-03-17	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	57,606	44.41	$2,558,282.46	4,841	4
2025-03-17	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	7,879	44.21	$348,330.59	18,672	4
2025-03-17	Heron, Patrick J	Director	-	Indirect	Purchase	21	43.93	$922.53	168,672	4
2025-03-17	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	27,279	44.21	$1,206,004.59	138,641	4
2025-03-11	Heron, Patrick J	Director	-	Indirect	Purchase	963	43.77	$42,150.51	168,123	4
2025-03-07	Heron, Patrick J	Director	-	Indirect	Purchase	580	43.21	$25,061.80	165,825	4
2025-03-05	Heron, Patrick J	Director	-	Indirect	Purchase	267	44.55	$11,894.85	163,910	4
2025-03-04	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	14,850	45.66	$678,051.00	12,111	4
2025-03-03	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	40,000	46.90	$1,876,000.00	115,920	4
2025-02-03	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	1,064	48.22	$51,306.08	4,232	4
2025-02-03	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	2,627	48.22	$126,673.94	26,961	4
2025-02-03	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	9,102	48.22	$438,898.44	115,920	4
2025-01-24	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	902	47.92	$43,223.84	3,524	4
2025-01-24	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	3,177	47.92	$152,241.84	29,588	4
2025-01-24	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	6,837	47.92	$327,629.04	125,022	4
2025-01-17	Quan, Joanne	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	6,969	45.86	$319,598.34	5,649	4
2025-01-07	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	1,998	42.82	$85,554.36	27,015	4
2025-01-07	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	7,489	42.82	$320,678.98	119,359	4
2025-01-07	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	750	42.82	$32,115.00	2,926	4
2024-11-14	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	2,500	47.10	$117,750.00	2,426	4
2024-09-18	Heron, Patrick J	Director	-	Indirect	Purchase	115	37.40	$4,301.00	162,308	4
2024-09-06	Heron, Patrick J	Director	-	Indirect	Purchase	230	41.58	$9,563.40	162,193	4
2024-07-02	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	375	34.00	$12,750.00	2,426	4
2024-06-24	Vig, Pamela	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	30,559	34.00	$1,039,006.00	27,406	4
2024-06-05	Ramasastry, Saira	Director	-	Direct	Sale	5,000	25.68	$128,400.00	0	4
2024-03-27	Bjerkholt, Eric	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	2,000	24.80	$49,600.00	14,000	4
2024-03-25	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	4,303	25.80	$111,017.40	29,013	4
2024-03-18	Bjerkholt, Eric	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	2,000	25.80	$51,600.00	12,000	4
2024-02-02	Vig, Pamela	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	1,214	26.19	$31,794.66	28,691	4
2024-02-02	Longpre, Lara	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	847	26.19	$22,182.93	104,407	4
2024-02-02	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	735	26.19	$19,249.65	1,759	4
2024-02-02	Peetz, Christopher	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	6,013	26.19	$157,480.47	104,112	4
2024-02-02	Radovich, Peter	Officer	PRESIDENT AND COO	Direct	Sale	1,790	26.19	$46,880.10	34,695	4
2024-01-08	Howe, Jolanda	Officer	SVP, GLOBAL CONTROLLER	Direct	Sale	528	28.04	$14,805.12	722	4
2024-01-08	Radovich, Peter	Officer	CHIEF OPERATING OFFICER	Direct	Sale	1,408	28.03	$39,466.24	36,485	4
2024-01-08	Longpre, Lara	Officer	CHIEF DEVELOPMENT OFFICER	Direct	Sale	1,019	28.04	$28,572.76	105,254	4
2024-01-08	Vig, Pamela	Officer	HEAD OF RESEARCH & DEVELOPMENT	Direct	Sale	1,408	28.03	$39,466.24	29,905	4
2024-01-08	Peetz, Christopher	Director,Officer	PRESIDENT AND CEO	Direct	Sale	5,209	28.03	$146,008.27	110,125	4
2023-12-05	Howe, Jolanda	Officer	SVP, Global Controller	Direct	Sale	2,500	32.40	$81,000.00	0	4
2023-11-09	Heron, Patrick J	Director	-	Indirect	Purchase	2,910	28.30	$82,353.00	161,963	4
2023-09-14	Grey, Michael G	Director	-	Direct	Sale	14,216	32.00	$454,912.00	0	4
2023-09-13	Heron, Patrick J	Director	-	Indirect	Purchase	2,625	31.02	$81,427.50	159,053	4
2023-09-12	Heron, Patrick J	Director	-	Indirect	Purchase	3,750	30.60	$114,750.00	156,428	4
2023-09-11	Bjerkholt, Eric	Officer	Chief Financial Officer	Direct	Purchase	10,000	29.65	$296,500.00	10,000	4
2023-08-31	Heron, Patrick J	Director,TenPercentOwner	-	Indirect	Purchase	147,991	26.25	$3,884,763.75	147,991	4
2023-08-25	Howe, Jolanda	Officer	SVP, Global Controller	Direct	Sale	3,459	26.23	$90,729.57	0	4
2023-07-03	Howe, Jolanda	Officer	SVP, Global Controller	Direct	Sale	915	25.65	$23,469.75	3,459	4
2023-07-03	Vig, Pamela	Officer	Head of Research & Development	Direct	Sale	1,425	25.65	$36,551.25	30,786	4
2023-07-03	Radovich, Peter	Officer	Chief Operating Officer	Direct	Sale	1,425	25.65	$36,551.25	37,675	4
2023-07-03	Longpre, Lara	Officer	Chief Development Officer	Direct	Sale	1,004	25.65	$25,752.60	105,839	4
2023-07-03	Peetz, Christopher	Director,Officer	President and CEO	Direct	Sale	5,498	25.65	$141,023.70	115,334	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

110.81%

Inst. Shares: 65,211,191

Shares Outstanding: 58,851,021

2025-12-31

116.06%

Inst. Shares: 58,259,547

Shares Outstanding: 50,198,304

2025-09-30

108.78%

Inst. Shares: 55,087,069

Shares Outstanding: 50,639,231

2025-06-30

105.67%

Inst. Shares: 52,548,373

Shares Outstanding: 49,726,823

2025-03-31

103.94%

Inst. Shares: 50,817,010

Shares Outstanding: 48,889,058

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	65,211,191	58,851,021	110.81%
2025-12-31	58,259,547	50,198,304	116.06%
2025-09-30	55,087,069	50,639,231	108.78%
2025-06-30	52,548,373	49,726,823	105.67%
2025-03-31	50,817,010	48,889,058	103.94%
2024-12-31	49,492,440	47,522,594	104.15%
2024-09-30	49,941,264	47,782,619	104.52%
2024-06-30	51,325,393	47,235,080	108.66%
2024-03-31	50,994,958	46,927,550	108.67%
2023-12-31	49,151,380	40,885,124	120.22%
2023-09-30	47,946,132	41,098,920	116.66%
2023-06-30	36,383,843	38,107,334	95.48%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Mirum Pharmaceuticals, Inc. (MIRM) — SEC Financial Statements & Analysis

Mirum Pharmaceuticals, Inc. (MIRM) is a pharmaceutical preparations company, incorporated in DE. Mirum Pharmaceuticals, Inc. trades on Nasdaq as: MIRM. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Mirum Pharmaceuticals, Inc. reported a 44.02% year-over-year revenue growth, a Gross Profit Margin of 81.39% (TTM), a Debt-to-Equity ratio of -101.27x, a Price-to-Sales (P/S) ratio of 12.00x (TTM), a Price-to-Book (P/B) ratio of -711.88x (TTM), at a market cap of $7.42B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 44.02%
Gross Profit Margin TTM: 81.39%
Debt To Equity: -101.27x
P/S TTM: 12.00x
P/B TTM: -711.88x
Market Cap: $7.42B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Mirum Pharmaceuticals, Inc. in?

Mirum Pharmaceuticals, Inc. (MIRM) operates in the Pharmaceutical Preparations industry.

What is MIRM's market cap?

Mirum Pharmaceuticals, Inc. (MIRM) has a market capitalization of $7.42B as of 2026-06-30.

What exchange does MIRM trade on?

Mirum Pharmaceuticals, Inc. (MIRM) trades on the Nasdaq.

Where is Mirum Pharmaceuticals, Inc. incorporated?

Mirum Pharmaceuticals, Inc. is incorporated in DE.